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The American National Institute for Mental Health (NIMH) has put out a set of research goals that include a long-
term plan to identify more reliable endogenous explanations for a wide variety of mental health disorders (Insel,
2013). In response to this, we have identified a major symptom that underlies multiple mental health disorders –
social bonding dysfunction. We suggest that endogenous opioid abnormalities can lead to altered social bonding,
which is a symptom of various mental health disorders, including depression, schizophrenia and ASD. This article
first outlines how endogenous opioids play a role in social bonding. Then we show their association with the
body’s inflammation immune function, and review recent literature linking inflammation to mental health
‘immunophenotypes’. We finish by explaining how these immunophenotypes may be caused by alterations in the
endogenous opioid system. This is the first overview of the role of inflammation across multiple disorders where
we provide a biochemical explanation for why immunophenotypes might exist across diagnoses. We propose a
novel mechanism of how the immune system may be causing ‘sickness-type’ behaviours (fatigue, appetite change,
social withdrawal and inhibited motivation) in those who have these immunophenotypes. We hope that this novel
aetiology can be used as a basis for future research in mental health.1. Background
While the aetiology of many disorders is still not well-understood,
psychiatrists are more widely accepting that there are ‘subtypes’ of
different mental health disorders, such as for depression (Kessing, 2007;
Preskorn, 2011). On top of this, Allsopp et al. (2019) have argued that
there is a large amount of ‘symptom overlap’ between different mental
health diagnoses (p. 19), which suggests that simple diagnostic labels
such as depression are catch-all terms that are not entirely useful. It is
also likely that different ‘subtypes’ require different treatments (Fried,
2017). Allsopp et al. (2019) conclude that “by focusing on diagnostic
categories … specific causal pathways may be obscured” (p. 21). This
may be why, even with the current symptom-based approach to labelling
mental health disorders, the use of ‘depression’ as an umbrella diagnosis
has been shown to lead to an unreliable description of symptoms, where
there can be 1030 unique symptom-profiles across 3703 patients (Fried
and Nesse, 2015). The unreliability of a label predicting symptom pro-
files is still not removedwhen using ‘subtype’ terms such as ‘melancholic’
or ‘atypical’ depression (Łojko and Rybakowski, 2017). This variety of
symptom profiles for the same diagnosis suggests that diagnostic labels,.J. Charles).
ber 2019
evier Inc. This is an open access ain their current form, may not be appropriate for describing a patient’s
condition.
Depression is not unique among mental health disorders in this re-
gard; other common disorders have had related criticisms levied against
them. One of these disorders is schizophrenia, which is seen by some as
an umbrella term for multiple conditions with similar presentations that
have different causal factors and treatment directions (Gillespie et al.,
2017; Lasalvia and Tansella, 2013; van Os et al., 1999; Wimberley et al.,
2016). Autism spectrum disorder (ASD) has been proposed to have
multiple possible endocrinological causes, where either low or excessive
levels of certain neurotransmitters give rise to ASD-like presentation (e.g.
Pellissier et al., 2018). Social anxiety disorder (SAD; aka social phobia)
likely has a subtype where serotonin plays a key role, while other sub-
types have unknown aetiologies (Stein and Andrews, 2015).
The use of umbrella-term diagnoses based on wide-ranging symp-
toms, instead of an aetiology-based diagnosis, means that the direction of
treatment that is chosen for patients is frequently not effective. For
example, those with so-called ‘treatment resistant’ depression. This is a
term used to describe those who have depression that do not respond to
at least one treatment. By definition, these patients do not benefit fromrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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make up a large proportion of those with a depression diagnosis (Nem-
eroff, 2007; Murphy et al., 2017), with only 35% of patients going into
full remission with their first pharmacological treatment (Kautzky et al.,
2019). It is only upon attempting more than one treatment method that
the remission rates lower (Murphy et al., 2017). ‘Treatment resistance’
that can go into remission when using a second or third treatment option
implies that ‘treatment resistant’ is a misnomer. That it can be treated,
but only with different therapies, suggests that the initial treatment given
to these patients was not appropriate for the aetiology of their mental
health condition. Thus, much ‘treatment resistance’ is likely to stem from
providing a treatment that, while attempting to address the diagnostic
label, fails to tackle the actual neurochemical causes of the symptoms in
each patient.
In light of this, it is important that healthcare providers and re-
searchers start to explore different methods of deciding initial treatment
plans for those with mental health disorders. Instead of using the um-
brella diagnostic labels as the main determinant of treatment direction,
there should be an attempt to determine the aetiology of the disorder
first. This will then allow for a more appropriate treatment plan, which
will in turn save patients and healthcare professionals time, money and
possibly lives. This is why the NIMH has a long-term plan to identify
more reliable endogenous explanations for a wide variety of mental
health disorders (Insel, 2013).
One possible way forward is provided by Akil et al. (2018), who have
suggested the use of a multi-scale systems approach, which focuses on
“identifying the brain circuits that are dysfunctional in several animal
models of depression as well the changes in gene expression that are
associated with these models” (p. 272). We build on this approach by
using evidence from multiple sub-fields to propose an aetiology for a
subset of those with apparently separate mental health diagnoses that
have a similar central symptom – social bonding deficits. To do this, we
explore the role of inflammation and endogenous opioids (EOs) as
possible neurochemical mechanisms for these deficits.
We will first look at the role of EOs in social bonding to establish a
theoretical basis for EO abnormalities as a potential aetiology for deficits
in social bonding. After this, we will show the role EOs play in the body’s
inflammation immune function. Then, we will outline recent research
showing the role of the immune system, in the form of inflammation, on
mental health disorders and, finally, we provide evidence that EO ab-
normalities are a possible cause for subtypes of mental health disorders
that involve social bonding deficits. In doing this, we not only hope to
help further the NIMH’s long-term plan to find endogenous causes for
mental health disorders, but also answer calls from other researchers to
integrate inflammation and social bonding research (Gassen and Hill,
2019) while ensuring that we do so in a more pragmatic approach to
mental health (Allsopp et al., 2019).
2. Endogenous opioids and social bonding
Endogenous Opioids (EOs) are a type of neurotransmitter that consist
of different ‘families’, endorphins, enkephalins and dynorphins being the
three best-known of these (see Benarroch, 2012 for a review of their
chemical precursors, production and release as well as information on the
other families). These families each preferentially bond to one of 3 types
of opioid receptors. Endorphins have a preferential binding specificity for
the μ-opioid receptor (MOR), enkephalins for the δ-opioid receptor
(DOR), and dynorphins for the κ-opioid receptor (KOR).
Jaak Panksepp was first to note that opioids likely play a role in
bonding processes (Panksepp et al., 1978, 1980a, 1980b; Nelson and
Panksepp, 1998). He noted that “brain opioids constitute the brain
neurochemical system for which we have the most extensive evidence for
a key role in the specific control of social-affective processes” (Panksepp
et al., 1986 p. 20). While his research was largely based on mother-infant
bonding, many others have argued that the link between EOs and all
types of social bonding has parallels with the behaviour of narcotics2addicts and those who form close relationships (Panksepp, 1999; Insel,
2003; Burkett and Young, 2012). Burkett and Young (2012) go so far as
to argue that ‘social attachment may be understood as a behavioural
addiction’ (p. 1) in some sense, where they also provide a comparison of
each of the diagnostic criteria for substance (opioid) addiction from the
DSM at the time (DSM IV-TR) with a related behaviour in social attach-
ments (p.43).
More recently, the ‘Brain-Opioid Theory of Social Attachment’
(BOTSA) has re-popularised in the context of primate and human social
bonding (Dunbar, 2009; Machin and Dunbar, 2011). In BOTSA, Machin
and Dunbar (2011) suggest that it is EOs that play the key role in social
bonding over oxytocin and other nonapeptides like arginine vasopressin,
which attracted considerable research interest in the early 21st century
(Dunbar, 2007), whose effects have been overstated (Bakermans-Kra-
nenburg and van IJzendoorn, 2013; Bakermans-Kranenburg and van
IJzendoorn, 2014; Benjamin et al., 2012; Nave et al., 2015). EOs have
been linked to maternal and infant bonding (Panksepp et al., 1980a,
1980b; Kalin et al., 1995; Barr et al., 2008), grooming behaviour (Martel
et al., 1995), as well as kin relationships, separation anxiety and play
behaviour (Vanderschuren et al., 1995). One of the key opioid neuro-
transmitters that Machin and Dunbar (2011) highlight is the
MOR-preferred β-endorphin (βe; Keverne et al., 1989).
Evidence for BOTSA comes from multiple fields, including work in
animal models. It has been found that MOR receptors play a necessary
role in adult social bonding (Burkett et al., 2011, p. 2207), a finding
which has been confirmed with other non-primate animal models (Gar-
du~no-Gutierrez et al., 2013; Kelm-Nelson et al., 2013; Kobayashi et al.,
2013; Parra-Gamez et al., 2013; Resendez et al., 2013). Other studies
have used nonhuman primates to understand the role of EOs in the social
bonding process. Ragen et al. (2015) looked at monogamous titi monkeys
in two experiments. They found that a MOR agonist reduced separation
anxiety, while a MOR antagonist lead to increases in stress hormone
release during separation, suggesting a role of EOs in bonding mainte-
nance and the stress response.
Another field of research that has explored the role of EOs on social
bonding is research with human participants. For example, Nummenmaa
et al. (2015) found that MOR density correlates with attachment style.
Mu-opioid ligands are natural painkillers (Zubieta et al., 2001; Zubieta
et al., 2003a,b), but do not readily pass through the blood brain barrier
(Witt and Davis, 2006). As a result, pain threshold or pain tolerance has
been used as an experimental proxy for mu-opioid release in the central
nervous system (Cohen et al., 2010; Tarr et al., 2015; Tarr et al., 2016).
Cohen et al. (2010) found that pain threshold increased by a larger
amount after group exercise compared to equally demanding solo exer-
cise, suggesting that MOR release is related to group activity, not just
exercise in general. Johnson and Dunbar (2016) found that pain
threshold predicted social network size, which further suggests that MOR
activity may be related to social bonding in some way.
Løseth et al. (2014) created a model that builds on BOTSA, which they
described as the ‘State-dependent μ-Opioid Modulation of Social Moti-
vation Model’ (Løseth et al., 2014, p. 9). They suggest that the MOR
system differentially modulates positive and negative affect in relation to
social bonding. Rejection, a negative stimulus, causes activation of MORs
in the bilateral amygdala, periaqueductal grey area and the ventral
striatum (Hsu et al., 2013), whilst acceptance, a positive stimulus, leads
to increased MOR activation in the right insula and the left amygdala
(Hsu et al., 2013). They cite the role of EOs as pain modulators to suggest
that MOR activation plays a key part in social motivation by either
alleviating distress (if one has an initial state of distress) or increasing
resistance to rejection (if one is initially comfortable). The understanding
of the interplay between MOR activation and social motivation has been
further developed by Pellissier et al. (2018) in their ‘μ-opioid receptor
balance’ (MOR-Balance) model. The MOR-Balance model proposes a
bell-curve for ideal MOR activation regarding social bonding (Fig. 1),
where too little activation causes social withdrawal, and over-activation
causes social indifference.
Fig. 1. The μ-receptor balance model (adapted from Pellissier et al., 2018):
Activity of μ-opioid receptors (MOR) competes with social avoidance systems
(SAS) to drive social behaviours. In a window of optimal functioning, MOR
activity is balanced with SAS to allow adaptive social behaviour. These condi-
tions are ideal to detect social reward. On the left part of the curve, low MOR
activity, e.g. due to social distress, pharmacological antagonism or genetic
anomaly, leads to reduced social reward and leaves the field clear for SAS to
elicit social withdrawal. On the right part of the curve, excessive MOR activity,
due to intense and/or prolonged exposure to opioid ligands or increased MOR
expression, saturates the reward system and produces social indifference.
Importantly, under this model, blocking MOR activity in the case of excessive
tone, or stimulating MOR when the tone is too low can restore normal, adaptive
social behaviour.
S.J. Charles et al. Brain, Behavior, & Immunity - Health 1 (2020) 100003The purpose of this section was to summarise the role of the opioid
system in bonding behaviour, with a focus on how the balance of MOR
activation affects social bonding. This background knowledge is needed
to understand how changes in MOR activation may affect social bonding
function in those with mental health disorders.
3. Immune system and endogenous opioids
This section will focus on how MOR activity is regulated. There are
multiple mechanisms that can change MOR activation, from MOR gene
expression, to exposure to external opioid agonists or antagonists.
However, one of the more common endogenous modulators of MOR
activation is the feedback process it has with the immune system. Im-
mune function is a complex system, split into the ‘innate’ and ‘adaptive’
immune response that is regulated by multiple hormones and neuro-
transmitters. As part of this complex network, the immune system uses a
feedback loop with MOR activation to help regulate itself. This section
will briefly explain this interplay, with a focus on inflammation.
Inflammation is a key function of the immune system, which is usu-
ally well-regulated by the innate immune response (Barton, 2008). The
purpose of inflammation is three-fold; (1) it allows the host to defend
against infection; (2) it activates the tissue repair response; and (3), as a
response to stress and homeostatic change, it prompts the host’s ho-
meostatic mechanisms (Medzhitov, 2008). The third of these, stress, is
considered an endogenous trigger for inflammation while pathogens and
tissue damage are exogenous triggers (Medzhitov, 2008 p. 430).
Inflammation is regulated by a different part of the immune system that is
brought into action during the inflammation process via the release of
various neurotransmitters by immune cells. One type of neurotransmitter
released in this process is opioids. Both the innate and adaptive immune
systems have methods of releasing opioids during inflammation for this
regulation (Plein and Rittner, 2018, p. 2722).
In a recent review article, Liang et al. (2016) developed an overview of
how opioids and the immune system interact, suggesting that the EO system
plays a direct role on immune system function. They highlight that there is
an abundance of research showing that many immune cells have opioid
receptors (B€orner et al., 2009; Li et al., 2009;Wybran et al., 1979), especially
MOR receptors (Roy et al., 2006; B€orner et al., 2013) that directly change
immune cell activity. For example, Sarkar et al. (2012) have shown that
opioids trigger the release of Natural Killer (NK) cells that fight off potential
pathogens. Given that the immune system also releases opioid ligands into
the body, a feedback loop is created between level of inflammation and level
of circulating opioids. Under normal conditions, this feedback loop is
well-regulated. However, under chronic stress this immune response may be
altered such that there is an increase in overall inflammatory activity (Glaser
and Kiecolt-Glaser, 2005), causing longer-term damage to the organism and
increasing risk for numerous major physical diseases (Manabe, 2011).
Various problems may arise if the feedback loop is dysfunctional. For
example, an overabundance of MOR agonists can lead to an increase in the
rate and levels of inflammation (Nguyen et al., 2014). This interplay between
the inflammatory immune response and MOR agonists has also been
observed in animal models (Sacerdote, 2006; Alves et al., 2012).
The feedback-loop between the inflammation response and EOs is
further demonstrated by the fact that multiple inflammation diseases are
linked to an up-regulation of opioid receptors (Jimenez et al., 2006),
where inflammation is associated with increased peripheral MOR sensi-
tivity (Hipolito et al., 2015), as well as changing MOR sensitivity in the
brainstem (Hipolito et al., 2015). In related work, Cahill and Taylor
(2017) have argued that this ‘neuroinflammation’ – the brain’s biological
response to inflammation-related pain and stress - may be the cause of
dysphoric symptoms seen in chronic exogenous opioid users. More spe-
cifically, they suggest these symptoms arise via mesocorticolimbic
pathway changes caused by neuroinflammation (Cahill and Taylor,
2017). The interplay between MOR activation by exogenous opioids and
an altered immune response has been the focus of other studies, which
show that some exogenous μ-opioids may cause immunosuppression3(Plein and Rittner, 2018). The changes to immune function that exoge-
nous opioids make provide further evidence for the regulatory role of
MOR activity in immune function, though it should be noted that we
don’t yet have a complete understanding of the role of opioid receptor
activity on the immune system. For example, while some exogenous
μ-opioids can cause immunosuppression (Plein and Rittner, 2018), not all
do (Sacerdote, 2006), and it is not clear why this is the case.
While neuroimmune pharmacology is a young discipline, especially
regarding opioid ligand function, our understanding is rapidly growing
(see Cosentino andMarino, 2018). We now are aware that the EO system,
especially MOR activation, plays a key role in the inflammation that takes
place during the immune response. Combining the knowledge of the role
of MOR activation on both social bonding and on the immune system
may allow us to better contextualise the link that has been found between
inflammation, immune biomarkers, and mental health disorders.
4. Mental health and the immune system
It has recently been suggested that there are subtypes of mental health
disorders where immunological irregularities are apparent (Miller et al.,
2013; Lamers et al., 2018a,b). These subtypes have been called ‘immu-
nophenotypes’ (Pennix et al., 2018). This realisation occurred as research
emerged showing that various mental health disorders are correlated
with abnormal levels of immune biomarkers (for an overview of the
depression-inflammation literature, see Pariante, 2017). This research
has led scientists with different clinical foci to propose immunological
aetiologies for their mental health disorders of interest. For example,
Slavich and Irwin (2014) provide a plausible explanation for the onset of
depression by citing stress as a causative factor of inflammation, which
leads to depressive symptomology. They cite work linking inflammation
biomarkers to depression (e.g. Pariante and Lightman, 2008; Pariante
and Miller, 2001), with other work outlining possible roles of the
stress-immune response on mental health in general (Godoy et al., 2018).
However, in much of the research this is only true for a subset of those
with depression (Miller et al., 2013), i.e. this immunophenotype is a
subtype of depression, not an explanation of all depression.
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Autism Spectrum Disorders (ASD), Griffiths and Levy (2017) touch on
possible mechanisms that stem from mitochondrial dysfunction. One of
these explanations involves immune dysfunction and inflammation (p.
6–7). They note that a large body of research reports that abnormal
inflammation and immune dysfunction ismore common in those with ASD
than in the general population (Elias et al., 2015; Gesundheit et al., 2013;
Onore et al., 2012; Rossignol and Frye, 2014; Stigler et al., 2009). Rossi-
gnol and Frye (2014) highlight that a number of studies report evidence of
immune dysregulation and/or inflammation in individuals with ASD and
that in some studies, “biomarkers of inflammation or immune dysregula-
tion have been correlated with ASD severity” (p. 2), including some
showing neuroinflammation (e.g. Suzuki et al., 2013; Wei et al., 2011),
with evidence mounting for some to describe subtypes of ASD to be im-
mune disorders (Meltzer and Van de Water, 2017) or even autoimmune
disorders (Ashwood and Van de Water, 2004a; Ashwood and Van de
Water, 2004b). Bjørklund et al. (2016) conducted a literature review
where they outline the various differences seen in multiple immune cells,
such as NK cells, T cells and B cells, of those with ASD. In this review,
Bjørklund et al. (2016) describe the link between immune dysregulation,
neuroinflammation and ASD presentation and compare this with the im-
mune cells and inflammation of those with neurotypical development.
It is not just depression and ASD that are linked to inflammation.
There is also an abundance of research which shows increased levels of
pro-inflammatory biomarkers or decreased levels of anti-inflammatory
biomarkers in individuals with schizophrenia (Müller et al., 2015; Lee
et al., 2017; Tanaka et al., 2017), bipolar disorder (Muneer, 2016;
Rosenblat and McIntyre, 2016), borderline personality disorder (Kahl
et al., 2006) and anxiety in response to social stimuli (Inagaki et al.,
2012), leading to social anxiety disorder (Vogelzangs et al., 2013).
Moreover, the link between abnormal inflammation function and general
mental health dysfunction is further found in those with comorbid con-
ditions. The role of inflammation in the comorbidity of ASD and
schizophrenia is beginning to come to light (Prata et al., 2017; Zheng
et al., 2018). Similarly, depression and schizophrenia have a high level of
co-morbidity, where inflammation abnormalities have been suggested as
a possible aetiology for the comorbidity (Kucerova et al., 2015; Upthe-
grove et al., 2017).
This section has provided a brief outline of the array of research that
shows immune dysfunction, specifically inflammation, as a possible
aetiology for subtypes of multiple mental health disorders, and for the
high rates of comorbidity between mental health issues. In doing so, it is
becoming clear that old understandings of mental health disorders hav-
ing a single aetiology, such as dopamine abnormalities as the cause of
schizophrenia, or monoamine deficiencies as the cause of depression, can
no longer be used as the de facto basis of treatment plans.
5. The role of endogenous opioids in social bonding disorders
Given the role of opioids in social bonding and the immune system
alongside the discovery of inflammation-based mental health disorders,
the possibility that the opioid system plays a key role in some subtypes of
social bonding-related mental health is of particular relevance for
rethinking the aetiology and treatment of various conditions. As outlined
in section 2, the EO system plays a major role in regulating social bonding
and social behaviour. This is extremely relevant to mental health disor-
ders because of the social deficits that are considered key symptoms for
many such disorders. For example, a major symptom for depression is the
loss of motivation for social contact (NHS, 2016), while negative symp-
toms of schizophrenia are anhedonia and asociality (Blanchard and
Cohen, 2006). Similarly, social deficits are a definitional symptom in
some disorders, such as ASD (Criterion A, DSM-5, American Psychiatric
Association, 2013).
In the stress-inflammation aetiology for depression proposed by Sla-
vich and Irwin (2014), much like most research linking the immune
system and mental health issues, the focus is on inflammatory cytokines,4such as IL-1, IL-6, and TNF-α. This focus on cytokines is prevalent
throughout the literature associating immune function with mental
health disorders (e.g. Lee et al., 2017; Pariante, 2017; Tanaka et al.,
2017). As a result, these immune markers can be linked to the ‘negative’
symptoms of disorders, i.e. those symptoms which describe an absence of
a behaviour, thought or feeling that is no longer present, by describing
them as ‘sickness behaviours’ typical of mental health disorder subtypes
(Moieni and Eisenberger, 2018). Examples of these sickness behaviours
include social withdrawal, anhedonia, change of appetite and loss of
motivation (e.g. Dantzer et al., 2008; Raison and Miller, 2013).
A recent large-scale study (n¼ 15,071) sought to test the ‘sickness
behaviour’ hypothesis by collecting data about specific symptoms of
those diagnosed with depression and concentration of the inflammation
biomarker C-reactive protein (CRP; Jokela et al., 2016). They found that
those who suffer from depression with increased levels of CRP are more
likely to experience greater ‘illness’ symptoms such as fatigue, appetite
change, social withdrawal, and inhibited motivation. The relationship
between inflammation biomarkers and specific depression symptoms has
been further supported by other studies. For example, Gallagher et al.
(2017) conducted a longitudinal study on 562 participants and looked at
CRP and specific symptoms. They found that those with greater levels of
CRP had higher rates of amotivation, less sadness and greater medical
co-morbidity over time than those with lower levels of CRP (also see
Lamers et al., 2018a,b). Similar findings of increased levels of these
‘sickness type’ behaviours can be found in the ASD (Wei et al., 2011;
Suzuki et al., 2013; Meltzer and Van de Water, 2017) and schizophrenia
literature (Carrizo et al., 2008; Garcia-Rizo et al., 2012; Suvisaari et al.,
2011; Meyer et al., 2011).
The link between inflammation and specifically the ‘negative’
symptoms of mental health disorders is important to note. The symptoms
mentioned in these studies – fatigue, appetite change, social withdrawal,
inhibited motivation and lowered levels of sadness – are the same as the
side-effects of opioid drug use, especially mu-opioid drugs such as heroin,
oxycodone and morphine. Given the similarity between mu-opioid nar-
cotics users and those with an immunophenotype of depression, it is very
likely that increased EO sensitivity or increased MOR activity play a role
in the immunophenotype of mental health disorders. While an immu-
nophenotype has multiple possible environmental or genetic causes for
onset, the EO system is a strong candidate for an explanation for their
onset. The remainder of this section will outline why we suspect that is
the case.
Stress is one of the environmental cues of interest in most research on
immunophenotypes (Corcoran et al., 2003; Polter and Kauer, 2014;
Slavich and Irwin, 2014). For example, the link between stress and
depression has been suggested to be specific to ‘atypical depression’, a
subtype of depression that is most associated with the immunophenotype
(Rudolf et al., 2014; Lamers et al., 2018a,b). Those diagnosed with
atypical depression are also noted to have a stronger reaction specifically
to the stress of interpersonal rejection (Łojko and Rybakowski, 2017).
This increased sensitivity to social-specific stressors in those most likely
to have an immunophenotype of depression further emphasises the
possibility that changes to the EO system could be a possible cause.
The effects of stress on opioid receptors are a further reason to
consider that EO abnormalities play a role in mental health conditions.
There is a growing body of work showing that stress can change the
expression of MOR receptors via epigenetics (Nikulina et al., 1999;
Nikulina et al., 2005; Chong et al., 2006; Hwang et al., 2009; Oertel et al.,
2012). This epigenetic change is found more specifically in brain areas
where EOs and dopamine are released to play a role in social reward and
motivation – the ventral tegmental area (Nikulina et al., 1999). This, in
combination with the μ-opioid role in the immune system, covered in
section 3, indicates that the alterations in social behaviour seen in those
who have the ‘immunophenotype’ of various mental disorders could be
caused by changes in MOR receptor activity.
Another factor that points toward a link between EO abnormalities
and mental health disorders, is that it has been noted that depression and
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2010; Tarr et al., 2015; Tarr et al., 2016) – have a strong link to one
another (Li, 2015). There is a lower pain threshold (PT) in depressed
patients (Adler and Gattaz, 1993; Marazziti et al., 1998) compared to
their non-depressed counterparts. Though, PT differences in depressed
patients are modality-specific: PT is increased for electric and heat-based
pain, but reduced in ischemic pain (Bagnato et al., 2018; B€ar et al., 2005;
Thompson et al., 2016). The difference in threshold between pain mo-
dalities could be because different pain modalities are related to different
types of opioid receptors (Scherrer et al., 2009). In mouse models, DORs
are responsible for mechanical (ischemic) pain, whereas MORs are
responsible heat-related pain (Scherrer et al., 2009; Wang et al., 2018).
As such, a systematic up-regulation of MOR could explain the increased
resistance to heat-related pain seen in depressed patients. Similarly, the
decreased tolerance to ischemic pain may also suggest altered DOR
functioning. This link between PT and depression is in addition to the
increased rate of depression found in those with disorders related to pain
perception, e.g. chronic pain (Lepine and Briley, 2004).
Similar findings of altered pain perception are shown in the schizo-
phrenia literature, too (Sakson-Obada, 2017; Urban-Kowalczyk et al.,
2015; Stubbs et al., 2015). Stubbs et al. (2015) conducted a meta-analysis
of all research conducted on pain perception in those with schizophrenia
compared to healthy controls and found a consistent, moderate effect
that those with schizophrenia-spectrum disorder had elevated pain
thresholds (Hedge’s g¼ 0.493), with an even higher effect size in those
who were not prescribed anti-psychotics (g¼ 0.599), and an increased
pain tolerance (g¼ 0.566) and threshold (g¼ 0.696) in those with a
diagnosis of schizophrenia. Something worthy of note is that most studies
on schizophrenia and pain perception are conducted using electrical or
thermal pain (Sakson-Obada, 2017), which suggests elevated MOR ac-
tivity. This elevated level of MOR activation is supported by recent
research showing increased concentrations of β-endorphin in both ani-
mal models of schizophrenia (Sz}ucs et al., 2016) and in patients with
schizophrenia (Urban-Kowalczyk et al., 2015) as well as reduced MOR
availability in brains of patients with negative symptoms of schizo-
phrenia (Ashok et al., 2017).
Further evidence that mental health issues may be linked to EO dif-
ferences comes from research suggesting that mental health disorders and
pain sensitivity share neuroanatomical circuitry, specifically, the lateral
habenula (LHb) (Li et al., 2016, 2017; Lawson et al., 2017; Morris et al.,
1999). Li and colleagues (2016; 2017) have proposed that the LHb, a re-
gion believed to play a role in avoidance behaviours (Shumake et al.,
2010) shows an altered activation in those with depression. Given the LHb
has a different level of activation in depressed patients compared to
healthy controls (Browne et al., 2018; Lawson et al., 2017; Morris et al.,
1999), and is related to avoidance, it is possible that this brain region plays
a role in the loss of social motivation seen in those with depression. The
LHb isn’t just related to depression; in animal models LHb lesions lead to
schizophrenia-like symptoms (Li et al., 2019). Moreover, the volume of the
bilateral Hb has been shown to be significantly lower in human patients
with schizophrenia compared to healthy controls (Zhang et al., 2017).
But how does this relate to EO release? The LHb has lowered activation
with the administration of the MOR agonist morphine (Benabid and
Jeaugey, 1989; Ma et al., 1992), and increased activation on morphine
withdrawal (Neugebauer et al., 2013). These findings are reported to be
related to MOR-related inhibition of LHb neurones in a patch-clamp
recording study (Margolis and Fields, 2016). The LHb receives differen-
tial input from, among other brain regions, the nucleus accumbens and has
a feedback loop with the ventral tegmental area (Bianco and Wilson,
2009). These are twomajor brain regions linked to reward andmotivation.
Furthermore, Le Foll and French (2018) provide evidence of certain genes
related to inflammation are up-regulated in the LHb for those more likely
to have anhedonia - a symptom that appears in both depression and psy-
chosis that is more likely to be found in those with the immunophenotype
of the disorders (Garcia-Rizo et al., 2012; Jokela et al., 2016). Le Foll and
French (2018) also note that some inflammation of the LHb may be linked5to opioid drug use. This provides further evidence that an immunophe-
notype could be related to altered MOR activation.
The MOR-Balance model for social bonding (Pellissier et al., 2018),
mentioned briefly in section 2, was originally proposed in the context of
ASD. In this model, Pellissier et al. (2018) provided a synthesis of many
studies that looked at the role of the opioid system’s role in ASD. In their
synthesis, they note an inconsistency in the literature as to whether it is
excess or insufficient MOR activity that leads to ASD presentation. There
were paradoxical findings from studies showing support for both possible
roles of MOR activity in ASD presentation. To account for this apparent
paradox, they proposed the MOR-Balance model (Fig. 1) for ASD, which
could explain the presence of ASD in a subset of those with neuroatypical
development. Given that ASD also has an immunophenotype (Wei et al.,
2011; Suzuki et al., 2013; Meltzer and Van de Water, 2017), the possi-
bility of EOs playing a role in social bonding mental health disorders is
one that should be considered seriously.
One final piece of evidence in support of the role of EOs in mental
health disorders concerns research on opioid-based treatments that exist
for depression and ASD. Research on EO-based treatments for mental
health disorders is occurring, but it is still either in early stages or has
fallen out of favour. Browne and Lucki (2019) published a comprehen-
sive breakdown of the evidence that endogenous opioid tone links to
depression and then cover research on new drugs currently going
through clinical trials. The four drugs that they cover in their paper are
Buprenorphine, ALKS-5461, JNJ-67953964 and BTRX-246040. The first
of these, Buprenorphine, may have some abuse potential, but at least one
derivative has beenmade that appears to reduce this issue, without losing
the anti-depressant effects (Almatroudi et al., 2018). The second of these
drugs, ALKS-5461, is a combination of Buprenophine with the
MOR-antagonist samidorphan. This combination is used to further
reduce abuse potential. While early research is positive, the Drugs
Advisory Committee of the FDA in the USA recommended that the drug’s
benefit-risk profile was not adequate to support approval. The third drug
they cover, JNJ-67953964, is a KOR antagonist. Evidence suggests that
the drug is more effective as a means to reduce substance abuse than for
specifically anti-depressant purposes. The fourth drug, BTRX-246040, is
a nociceptin-opioid receptor antagonist (note that NORs are mainly
related to pain perception) currently undergoing phase 2 trials. Research
on these opioid-based treatments for depression is still very much in its
early stages but it is a promising area.
In the late 20th century, research focus on the relationship between
ASD and inflammation used the ratio of CD4 to CD8 cells as a biomarker
for inflammation. This biomarker has since been superseded by others,
such as inflammatory cytokines. However, during this time, Scifo et al.
(1996) found that the use of Naltrexone, a MOR antagonist, produced a
significant reduction in ASD symptomology. They noted that the
“behavioural change was also accompanied by an increase of T-help-
er-inducers and decrease in T-cytotoxic-suppressor, resulting in a
normalization of the CD4/CD8 ratio” (p. 351). Other research looking at
the effect of Naltrexone on ASD also shows some improvement (Bouvard
et al., 1995; Campbell et al., 1993; Kolmen et al., 1995), especially with
self-injurious behaviour (Eichaar et al., 2006; Sandman and Kemp, 2011)
but only in a subgroup of those with ASD (Roy et al., 2015). Given the
MOR-Balance model of ASD proposed by Pellissier et al. (2018), this
subgroup may be the one with excessive MOR activity, compared to
others with ASD who have insufficient MOR activity or some other
biochemical cause of their symptoms. As the treatment only appeared
useful in a subgroup of those with ASD, not much more research on the
effectiveness of opioid agonists or antagonists for ASD has been con-
ducted. We would recommend that more research looks at their effec-
tiveness in sub-populations that appear to have an immunophenotype or
excessive circulating opioids. We believe that one avenue of research that
should receive greater prominence is pharmacological treatments for
mental health disorders that address dysfunctional opioid activity.
This section has offered several lines of evidence which suggest that
altered MOR activity plays a role in various mental health disorders: (1)
S.J. Charles et al. Brain, Behavior, & Immunity - Health 1 (2020) 100003Behavioural/symptomatic similarities between ‘sickness-type’ inflam-
mation disorders and chronic opioid drug users; (2) The role of stress on
MOR epigenetics, which could provide an explanation of the link be-
tween stress and the onset of mental health issues; (3) The link between
increased tolerance of heat-related pain, which is controlled by MOR
activation, and depression & schizophrenia; (4) The role of brain regions
that have MOR input, such as the LHb, in social reward and social
avoidance and the link between these regions and mental health issues;
(5) Differential MOR activation in those with social deficits in ASD; and
(6) Evidence of some remission from early stage research of opioid-based
pharmaceutical treatments for depression and ASD (see Fig. 2 for a visual
representation of these lines of evidence). These pieces of evidence add
up in the argument we make throughout this article, namely that changes
in the EO system, specifically abnormal MOR activity, is a possibleFig. 2. A visual representation of the evidence that mu-opioid receptor (MOR) activi
0. The feedback loop between the immune system and MOR activity means that if o
1. ‘Sickness’ behaviours that are cited as an example of immunophenotypes are t
substances
a. The previous proposed link between inflammation and these behaviours
2. Stress can lead to MOR dysfunction via changes to MOR epigenetics as well as vi
3. MOR dysfunction also leads to an altered pain response, which is seen in those wit
the co-morbidity between chronic pain and mental health issues.
4. The Lateral Habenula (LHb) functioning is altered by MOR and immune dysfunct
5. Pellissier et al. (2018) described how MOR activity, be it excessive or insufficien
6. Early stages of research on MOR-based pharmaceutical treatments for ASD & dep
6neurochemical mechanism behind the behaviour changes seen in those
with immunophenotypes of various mental health disorders.
6. Conclusion
Clinical applications of psychology have long struggled with the
tension between an understanding that mental health disorders have
various subtypes and treatment plans which treat these disorders as
monolithic, with a single aetiology. This problem arises, in part, from the
key-symptom-focused approach of the field, where individuals with
similar core cognitive-behavioural symptoms are reported to suffer from
the same disorder, without a precise understanding of the aetiology of
the other surrounding symptoms. We are not alone in pointing out the
importance of changing this approach: the American National Institute ofty plays a role in the aetiology of immunophenotypes of mental health disorders.
ne is dysfunctional, the other may well be dysfunctional.
he same behaviours as those shown by those who take exogenous mu-opioid
a immune response dysregulation.
h depression and schizophrenia and some report it in ASD. This may also explain
ion, leading to social withdrawal.
t, plays a role in social dysfunction.
ression are promising for a subgroup of those with these diagnoses.
S.J. Charles et al. Brain, Behavior, & Immunity - Health 1 (2020) 100003Mental Health’s long-term plan to identify more reliable endogenous
explanations for a wide variety of mental health disorders (Insel, 2013)
speaks to this. The present article seeks to address this plan, as well as
building on recent calls to action from researchers across fields (Allsopp
et al., 2019; Gassen and Hill, 2019).
Here, we have proposed a possible aetiology for a subtype of various
mental health conditions known as immunophenotypes. While we are
not the first to highlight the relevance of inflammation as a role in sub-
types of specific disorders such as depression (Lamers et al., 2018a,b;
Pariante, 2017), schizophrenia (Müller et al., 2015; Lee et al., 2017;
Tanaka et al., 2017) and ASD (Meltzer and Van de Water, 2017), this is
the first overview of the role of inflammation across multiple disorders
where a biochemical explanation for why immunophenotypes might
exist across diagnoses is provided.We propose a novel mechanism of how
the immune system may be causing ‘sickness-type’ behaviours (fatigue,
appetite change, social withdrawal and inhibited motivation) in those
who have these immunophenotypes. We have considered the role of a
malfunctioning endogenous opioid system – more specifically, we sug-
gest altered mu-opioid receptor activation as a possible mechanism.
Based on this hypothesis, we feel that encouraging new research into the
role of opioid abnormalities in mental health issues is of vital importance.
Such research may help increase the number of effective treatments that
healthcare professionals are able to turn to in order to help their patients
as well as allow for a better understanding of the biochemical un-
derpinnings of mental health disorders.
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